Phase 4
N=32,175
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Infections, Papillomavirus
Bottom Line
View on ClinicalTrials.gov: NCT00534638 ↗Enrolled (actual)
32,175
Serious AEs
1.1%
Results posted
Jan 2016
Primary outcome: Primary: Number of Female Subjects With Overall Vaccine Effectiveness Against Genital Infection With Human Papilloma Virus (HPV)-16/18 Types in Cervarix/Engerix-B B Group Versus Engerix-B Group and in Cervarix/Engerix-B A Group Versus Engerix-B Group — 139; 117; 329 Participants — p=0.004
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Cervarix (Biological); Engerix-B (Biological)
- Age
- Pediatric · 12+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Dec 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Female Subjects With Overall Vaccine Effectiveness Against Genital Infection With Human Papilloma Virus (HPV)-16/18 Types in Cervarix/Engerix-B B Group Versus Engerix-B Group and in Cervarix/Engerix-B A Group Versus Engerix-B Group |
139; 117; 329 | 0.004 sig |
| SECONDARY Number of Female Subjects With Overall Vaccine Effectiveness Against Genital Infection With HPV-16/18 Types in Cervarix/Engerix-B A Group Versus Cervarix/Engerix-B B Group |
139; 117 | 0.069 |
| SECONDARY Number of Female Subjects With Overall Vaccine Effectiveness Against Genital Oncogenic Infection With Specific HPV Types |
88; 85; 227; 62; 41; 134 | — |
| SECONDARY Number of Female Subjects With Total Vaccine Effectiveness Against Oropharyngeal Infection With HPV-16/18 Types |
9; 27 | — |
| SECONDARY Number of Female Subjects With Total Vaccine Effectiveness Against Oropharyngeal Oncogenic Infection With Specific HPV Types |
6; 19; 4; 10; 3; 9 | — |
| SECONDARY Number of Male Subjects Reporting Any and Grade 3 Solicited Local Symptoms, in a Subset of Subjects |
463; 157; 12; 1; 99; 90 | — |
| SECONDARY Number of Male Subjects Reporting Any, Grade 3 and Related to Vaccination Solicited General Symptoms, in a Subset of Subjects |
58; 58; 0; 1; 37; 45 | — |
| SECONDARY Number of Male Subjects Reporting Any, Grade 3 and Related to Vaccination Unsolicited Adverse Events (AEs), in a Subset of Subjects |
157; 202; 31; 46; 12; 19 | — |
| SECONDARY Number of Male Subjects With Urticaria/Rash Within 30 Minutes After Each Vaccination Dose, in a Subset of Subjects |
643; 1047; 0; 0; 634; 1042 | — |
| SECONDARY Number of Male Subjects Reporting Medically Significant Conditions (MSCs), in a Subset of Subjects |
47; 76 | — |
| SECONDARY Number of Male Subjects Reporting Any Serious Adverse Events (SAEs) and SAEs Causally Related to Vaccination, in a Subset of Subjects |
58; 25; 4; 1 | — |
| SECONDARY Number of Subjects Reporting SAEs Assessed by the Investigator as Possibly Related to Vaccination |
25; 30 | — |
| SECONDARY Number of Subjects With New Onset of Autoimmune Diseases (NOADs), Retrieved From Care Register for Social Welfare and Health Care (HILMO) |
149; 180 | — |
| SECONDARY Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies With Onset During the Study Period, Retrieved From Medical Birth Registry and HILMO |
254; 183; 454; 332; 5; 5 | — |
| SECONDARY Number of Subjects With HPV-16 and HPV-18 Antibody Concentrations Equal to or Above the Cut-off Values, by Gender, in a Subset of Subjects |
40; 536; 217; 86; 1163; 688 | — |
| SECONDARY Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations, by Gender, in a Subset of Subjects |
4.5; 23959.1; 2759.5; 4.5; 21327.2; 2609.6 | — |
Summary
Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of cancer-related death among women globally. The current study is designed to evaluate the overall impact of HPV immunization in adolescents 12-15 years of age.
Eligibility Criteria
Inclusion Criteria
- Study participants who the investigator or delegate believes that they and/or their parents/legally acceptable representative can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study.
- A male or female between, and including, 12 and 15 years of age at the time of the first vaccination.
A written informed assent must be obtained from all study participants prior to enrolment. In addition, a written informed consent must be obtained from the study participants' parent or legally acceptable representative.
Note: As according to the Finnish law legal age of consent is 15 years, a written informed consent form can be obtained from study participants aged 15 years old and their parent(s)/legally acceptable representative(s) will receive a letter informing them of their child participation to the study.
- Healthy male and female study participants as established by medical history before entering into the study. If needed, a history-directed clinical examination will be performed by the investigator or delegate (e.g. study nurse).
- Study participants must not be pregnant. Absence of pregnancy should be verified (e.g. urine pregnancy test) as per investigator's or delegate's clinical judgement.
- If the study participant is female, she must be of non-childbearing potential, i.e. be abstinent, have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal or pre-menarcheal, or if she is of childbearing potential, she must use adequate contraception for 30 days prior to vaccination and continue for 2 months after completion of the vaccination series.
Exclusion Criteria
- Previous vaccination against HPV or Hepatitis B virus.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
- Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature <37.5°C (99.5°F) / Axillary temperature <37.5°C (99.5°F) / Rectal temperature <38°C (100.4°F).)
- Pregnant or lactating female.
Data sourced from ClinicalTrials.gov (NCT00534638). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.